Monopar Therapeutics director Raymond Anderson sells $351,835 in stock

On August 25, 2026, Raymond Anderson, a director at Monopar Therapeutics, sold shares valued at $351,835, as disclosed in a recent Form 4 filing with the Securities and Exchange Commission. The sale was conducted through a pre-established Rule 10b5-1 trading plan, initiated on May 26, 2026. The shares sold were executed across multiple transactions, with prices ranging between $109.51 and $113.11 per share.

Anderson disposed of 3,142 shares in total, representing a weight of approximately 2.78% of the company's outstanding shares following its 5-to-1 reverse stock split on August 12, 2024. The sale occurred at a time when MNPR's stock price was hovering around $111.89, nearing its 52-week high of $124.82, and had experienced a remarkable 228% increase over the previous year.

Despite the significant sales, initial filings had omitted Anderson's two option exercises, totaling $94,260, executed at an exercise price of $30.00 per share. These option exercises were also conducted under the same Rule 10b5-1 plan. As a result of this transaction, Anderson directly owns 5,373 shares of Monopar Therapeutics common stock.

Monopar Therapeutics has been actively involved in various developments, including a rolling NDA submission for ALXN1840, a treatment for Wilson disease, following FDA authorization. This development has led analysts to raise their price targets for the company, with H.C. Wainwright and BTIG both maintaining Buy ratings. Additionally, Monopar has strengthened its commercial team and faced reactions from Cantor Fitzgerald, which downgraded the stock to Neutral while raising its price target.